Alcon is a medical device maker with a 9/9 Piotroski score and 198% cash conversion, but the price is within 3.3% of the analyst target, revenue growth is modest, and the stock is an overbought rally inside a downtrend.
Thesis pillars
- Strong Cash Conversion→Stable
- Limited Upside To Target→Stable
- Modest Growth Profile↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026
Alcon Inc. (ALC) Stock Analysis
Recovery setup
Healthcare · Medical Instruments & Supplies
Hold if already holding. Not a fresh buy at $77.31, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Earnings in 5 days (event risk).
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and... Read more
Hold if already holding. Not a fresh buy at $77.31, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Earnings in 5 days (event risk). Chart setup: Death cross but MACD improving, RSI 81. Maintain position. Not compelling to add more. Score 5.5/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 5d<=7d. Suitability: moderate.
Recent developments
updated Nov 4, 2026Recent Developments — Alcon Inc.
Latest news
- NEWS Alcon Shares Experience Significant Gains on the Swiss Market — fiscal.ai Nov 4, 2026 positive
- NEWS Algoma Central Corporation Closes $70 Million Offering — fiscal.ai Nov 4, 2026 neutral
- NEWS AlphaValue/Baader Europe Downgrades Alcon to Add — fiscal.ai Nov 2, 2026 negative
- NEWS Needham Maintains Buy Rating and $98 Price Target for Alcon — fiscal.ai Nov 2, 2026 positive
- NEWS Alcon Jumps 5.7% After Tariff Refund Drives Up 2026 Profit Forecast - TechStock² — TechStock² Aug 11, 2026 positive
Latest item Nov 4, 2026 · Generated 2026-11-05T11:49:09Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $77.31, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Earnings in 5 days (event risk). Chart setup: Death cross but MACD improving, RSI 81. Maintain position. Not compelling to add more. Analyst target $73.79 reached (−4.6%), stop $73.85 (−4.7%), A.R:R -0.3:1. Score 5.5/10, moderate confidence.
Analyst target $73.79 reached (−4.6% from $77.31); no take-profit level is published. Analyst target $73.79 reached (−4.6%), stop $73.85 (−4.7%), A.R:R -0.3:1. Stop-loss: $73.85.
Analyst target reached - limited upside remaining; Earnings in 5 days (event risk); Overbought (RSI 81).
Alcon Inc. trades at a P/E of 58.6 (forward 19.6). TrendMatrix value score: 4.9/10. Verdict: Hold.
22 analysts rate ALC, with a consensus score of 3.9/5. 16 analysts publish price targets averaging $82.
What does Alcon Inc. do?Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates...
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. In addition it also develops and commercializes therapies for chronic eye diseases, focusing on encapsulated cell therapy platforms for ocular conditions. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.